The opinion article is devoted to the analysis of a large-scale 24-week multinational observational prospective cohort study «The effectiveness of vortioxetine in depression in real clinical practice» (BELIEVE). The study demonstrated the achievement of functional recovery of patients with depressive disorder when using vortioxetine, good efficacy and tolerability of the drug for the treatment of depression in a large and heterogeneous patient population representative of everyday psychiatric practice. A significant improvement in depressive and cognitive symptoms, productivity and quality of life of patients was achieved, while the greatest effect was observed when using vortioxetine as the first line of therapy. The results of the study confirmed the data of numerous RCTs devoted to the use of vortioxetine in the treatment of depressive disorder, and they can be used when choosing tactics of antidepressant therapy in conditions of routine psychiatric.